This study is to evaluate the safety and effectiveness of an injectable slow releasing
preparation of naltrexone to reduce alcohol consumption and risk of relapse in
alcohol-dependent subjects. Individuals will receive either naltrexone or a placebo injection
for a total of three months, with two subsequent followup visits spanning a 6- month period.
Phase:
Phase 4
Details
Lead Sponsor:
UConn Health
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)